Andrew Baum has departed from his role at Pfizer, where he held the title of executive vice president and chief strategy and innovation officer.
Baum, who was formerly an analyst at Citi, was brought in to help revitalize Pfizer's strategic direction.
His resignation raises questions about the future of Pfizer's strategy as the company navigates ongoing challenges in the health sector.